Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma

David Brendan Price, D. Hernandez, P. Magyar, J. Fiterman, K. M. Beeh, I. G. James, S. Konstantopoulos, R. Rojas, J. A. van Noord, COMPACT Study Grp

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma.

Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 mug/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 mug/day (n=448) or budesonicle 1600 mug/day (n=441) for 12 weeks.

Results: Both groups showed progressive improvement in several measures of asthma control compared with baseline. Mean morning peak expiratory flow (AM PEF) improved similarly in the last 10 weeks of treatment compared with baseline in both the montelukast + budesonide group and in the double dose budesonide group (33.5 v 30.1 l/min). During days 1-3 after start of treatment, the change in AM PEF from baseline was significantly greater in the montelukast + budesonide group than in the double dose budesonicle group (20.1 v 9.6 l/min, p<0.001), indicating faster onset of action in the montelukast group. Both groups showed similar improvements with respect to "as needed" 0 agonist use, mean daytime symptom score, nocturnal awakenings, exacerbations, asthma free days, peripheral eosinophil counts, and asthma specific quality of life. Both montelukast + buclesonide and double dose budesonide were generally well tolerated.

Conclusion: The addition of montelukast to inhaled budesonide is an effective and well tolerated alternative to doubling the dose of inhaled budesonicle in adult asthma patients experiencing symptoms and inadequate control on budesonide alone.

Original languageEnglish
Pages (from-to)211-216
Number of pages5
JournalThorax
Volume58
Issue number3
DOIs
Publication statusPublished - 2003

Keywords

  • LEUKOTRIENE RECEPTOR ANTAGONIST
  • DOUBLE-BLIND TRIAL
  • QUALITY-OF-LIFE
  • CLINICAL-TRIALS
  • FLUTICASONE PROPIONATE
  • CORTICOSTEROIDS
  • BECLOMETHASONE
  • INFLAMMATION
  • SALMETEROL
  • CHILDREN

Cite this

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. / Price, David Brendan; Hernandez, D.; Magyar, P.; Fiterman, J.; Beeh, K. M.; James, I. G.; Konstantopoulos, S.; Rojas, R.; van Noord, J. A.; COMPACT Study Grp.

In: Thorax, Vol. 58, No. 3, 2003, p. 211-216.

Research output: Contribution to journalArticle

Price, DB, Hernandez, D, Magyar, P, Fiterman, J, Beeh, KM, James, IG, Konstantopoulos, S, Rojas, R, van Noord, JA & COMPACT Study Grp 2003, 'Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma', Thorax, vol. 58, no. 3, pp. 211-216. https://doi.org/10.1136/thorax.58.3.211
Price, David Brendan ; Hernandez, D. ; Magyar, P. ; Fiterman, J. ; Beeh, K. M. ; James, I. G. ; Konstantopoulos, S. ; Rojas, R. ; van Noord, J. A. ; COMPACT Study Grp. / Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. In: Thorax. 2003 ; Vol. 58, No. 3. pp. 211-216.
@article{26bc8a0d1af44791a52175acb253ea05,
title = "Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma",
abstract = "Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma.Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 mug/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 mug/day (n=448) or budesonicle 1600 mug/day (n=441) for 12 weeks.Results: Both groups showed progressive improvement in several measures of asthma control compared with baseline. Mean morning peak expiratory flow (AM PEF) improved similarly in the last 10 weeks of treatment compared with baseline in both the montelukast + budesonide group and in the double dose budesonide group (33.5 v 30.1 l/min). During days 1-3 after start of treatment, the change in AM PEF from baseline was significantly greater in the montelukast + budesonide group than in the double dose budesonicle group (20.1 v 9.6 l/min, p<0.001), indicating faster onset of action in the montelukast group. Both groups showed similar improvements with respect to {"}as needed{"} 0 agonist use, mean daytime symptom score, nocturnal awakenings, exacerbations, asthma free days, peripheral eosinophil counts, and asthma specific quality of life. Both montelukast + buclesonide and double dose budesonide were generally well tolerated.Conclusion: The addition of montelukast to inhaled budesonide is an effective and well tolerated alternative to doubling the dose of inhaled budesonicle in adult asthma patients experiencing symptoms and inadequate control on budesonide alone.",
keywords = "LEUKOTRIENE RECEPTOR ANTAGONIST, DOUBLE-BLIND TRIAL, QUALITY-OF-LIFE, CLINICAL-TRIALS, FLUTICASONE PROPIONATE, CORTICOSTEROIDS, BECLOMETHASONE, INFLAMMATION, SALMETEROL, CHILDREN",
author = "Price, {David Brendan} and D. Hernandez and P. Magyar and J. Fiterman and Beeh, {K. M.} and James, {I. G.} and S. Konstantopoulos and R. Rojas and {van Noord}, {J. A.} and {COMPACT Study Grp}",
year = "2003",
doi = "10.1136/thorax.58.3.211",
language = "English",
volume = "58",
pages = "211--216",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group Ltd",
number = "3",

}

TY - JOUR

T1 - Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma

AU - Price, David Brendan

AU - Hernandez, D.

AU - Magyar, P.

AU - Fiterman, J.

AU - Beeh, K. M.

AU - James, I. G.

AU - Konstantopoulos, S.

AU - Rojas, R.

AU - van Noord, J. A.

AU - COMPACT Study Grp

PY - 2003

Y1 - 2003

N2 - Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma.Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 mug/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 mug/day (n=448) or budesonicle 1600 mug/day (n=441) for 12 weeks.Results: Both groups showed progressive improvement in several measures of asthma control compared with baseline. Mean morning peak expiratory flow (AM PEF) improved similarly in the last 10 weeks of treatment compared with baseline in both the montelukast + budesonide group and in the double dose budesonide group (33.5 v 30.1 l/min). During days 1-3 after start of treatment, the change in AM PEF from baseline was significantly greater in the montelukast + budesonide group than in the double dose budesonicle group (20.1 v 9.6 l/min, p<0.001), indicating faster onset of action in the montelukast group. Both groups showed similar improvements with respect to "as needed" 0 agonist use, mean daytime symptom score, nocturnal awakenings, exacerbations, asthma free days, peripheral eosinophil counts, and asthma specific quality of life. Both montelukast + buclesonide and double dose budesonide were generally well tolerated.Conclusion: The addition of montelukast to inhaled budesonide is an effective and well tolerated alternative to doubling the dose of inhaled budesonicle in adult asthma patients experiencing symptoms and inadequate control on budesonide alone.

AB - Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma.Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 mug/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 mug/day (n=448) or budesonicle 1600 mug/day (n=441) for 12 weeks.Results: Both groups showed progressive improvement in several measures of asthma control compared with baseline. Mean morning peak expiratory flow (AM PEF) improved similarly in the last 10 weeks of treatment compared with baseline in both the montelukast + budesonide group and in the double dose budesonide group (33.5 v 30.1 l/min). During days 1-3 after start of treatment, the change in AM PEF from baseline was significantly greater in the montelukast + budesonide group than in the double dose budesonicle group (20.1 v 9.6 l/min, p<0.001), indicating faster onset of action in the montelukast group. Both groups showed similar improvements with respect to "as needed" 0 agonist use, mean daytime symptom score, nocturnal awakenings, exacerbations, asthma free days, peripheral eosinophil counts, and asthma specific quality of life. Both montelukast + buclesonide and double dose budesonide were generally well tolerated.Conclusion: The addition of montelukast to inhaled budesonide is an effective and well tolerated alternative to doubling the dose of inhaled budesonicle in adult asthma patients experiencing symptoms and inadequate control on budesonide alone.

KW - LEUKOTRIENE RECEPTOR ANTAGONIST

KW - DOUBLE-BLIND TRIAL

KW - QUALITY-OF-LIFE

KW - CLINICAL-TRIALS

KW - FLUTICASONE PROPIONATE

KW - CORTICOSTEROIDS

KW - BECLOMETHASONE

KW - INFLAMMATION

KW - SALMETEROL

KW - CHILDREN

U2 - 10.1136/thorax.58.3.211

DO - 10.1136/thorax.58.3.211

M3 - Article

VL - 58

SP - 211

EP - 216

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 3

ER -